Navigation Links
PTC Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update
Date:8/7/2014

SOUTH PLAINFIELD, N.J., Aug. 7, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the second quarter ended June 30, 2014.

"This has been an exciting quarter for PTC. In May we received a positive opinion from the CHMP for marketing approval for Translarna™ (ataluren) an investigational new drug in the US, for nonsense mutation Duchenne muscular dystrophy and we recently received the approval from the European Commission granting the conditional marketing authorization. It is an honor to bring the world's first therapy for Duchenne muscular dystrophy to patients who have been waiting too long for a treatment. We are actively focused on providing Translarna to patients as quickly as possible and are working aggressively to prepare for launch across the EU," stated Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "In addition to our efforts in nmDMD, we recently initiated our confirmatory Phase 3 clinical trial in nonsense mutation cystic fibrosis and it is our goal to initiate a Phase 2 proof-of-concept study for Translarna in a new indication, MPS I caused by a nonsense mutation, later this year. We expect the second half of the year will be a transformative time at PTC, as we expand our global commercial organization focused on our mission of bringing new therapies to patients with rare and neglected disorders."

Corporate Highlights:

  • ACT DMD: The confirmatory Phase 3 ACT DMD (Ataluren Confirmatory Trial in DMD) trial of Translarna™ (ataluren) in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) is well underway. Enrollment is expected to be completed near term with initial, top-line data available in the second half of 2015.
  • ACT CF: In June, the confirmatory Phase 3 ACT CF clinical trial was initiated. This tr
    '/>"/>

  • SOURCE PTC Therapeutics, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Pivotal Therapeutics To Explore Potential Commercial Partnership Opportunities in China
    2. Relmada Therapeutics, Inc. Completes Name Change and Announces New Ticker
    3. PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    4. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
    5. Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast
    6. Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation
    7. Abide Therapeutics Appoints Nancy Thornberry to Board of Directors
    8. PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2014 Financial Results
    9. Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse
    10. Particle Sciences and Eyeon Therapeutics Receive Patent on Novel Dry Eye Technology
    11. MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/4/2015)... Aug. 04, 2015 ... the addition of the "MRI Systems Market ... Operational Efficiency, with Growth Driven by Developing Economies" ... Systems Market to 2020 - Focus on Patient ... Developing Economies" discusses the market, competitive landscape, and ...
    (Date:8/4/2015)... Pharmaceuticals, Inc. (Nasdaq: ISIS ) today reported net ... three and six months ended June 30, 2015, respectively, ... $43.4 million for the same periods in 2014. Isis, ... more than $90 million of revenue Isis earned in ... Bayer to license  ISIS-FXI Rx .  Isis increased its ...
    (Date:8/4/2015)... 4, 2015 Research and Markets ( ... Jain PharmaBiotech,s new report "Transdermal Drug ... to their offering. This ... an approach used to deliver drugs through ... alternative to oral,intravascular, subcutaneous and transmucosal routes. ...
    Breaking Medicine Technology:Global MRI Systems Market Outlook to 2020 - Focus on Patient Comfort and Operational Efficiency, with Growth Driven by Developing Economies 2Isis Reports Financial Results And Highlights For Second Quarter 2015 2Isis Reports Financial Results And Highlights For Second Quarter 2015 3Isis Reports Financial Results And Highlights For Second Quarter 2015 4Isis Reports Financial Results And Highlights For Second Quarter 2015 5Isis Reports Financial Results And Highlights For Second Quarter 2015 6Isis Reports Financial Results And Highlights For Second Quarter 2015 7Isis Reports Financial Results And Highlights For Second Quarter 2015 8Isis Reports Financial Results And Highlights For Second Quarter 2015 9Isis Reports Financial Results And Highlights For Second Quarter 2015 10Isis Reports Financial Results And Highlights For Second Quarter 2015 11Isis Reports Financial Results And Highlights For Second Quarter 2015 12Isis Reports Financial Results And Highlights For Second Quarter 2015 13Isis Reports Financial Results And Highlights For Second Quarter 2015 14Isis Reports Financial Results And Highlights For Second Quarter 2015 15Isis Reports Financial Results And Highlights For Second Quarter 2015 16Transdermal Drug Delivery Report 2015-2024 - Technologies, Markets, and Companies Analysis 2
    (Date:8/4/2015)... , ... August 04, 2015 , ... An article ... financial incentives to be a viable method for encouraging people to lose weight. Specifically ... the future of their weight loss success, adding a financial incentive to the overall ...
    (Date:8/4/2015)... ... 04, 2015 , ... Angelina Jolie is in it at age 39. “It” ... Dr. Angela DeRosa, DO, MBA, CPE aka “Dr. Hot Flash,” arguably the ... out of menopause. , Myth #1: Menopause only affects old ladies. – Menopause ...
    (Date:8/4/2015)... ... August 04, 2015 , ... Worldwide Power Products acquires new ... its reach in Texas. Effective July 1st of this year, Worldwide Power Products ... With the North Texas acquisition, Worldwide Power Products (“WPP”) now services 1000 ...
    (Date:8/4/2015)... ... 04, 2015 , ... Recent studies in the ... in binge drinking among certain populations and specific locations. Researchers, who ... examine trends and evidence to help facilitate health care treatment to meet current ...
    (Date:8/4/2015)... ... 2015 , ... Members receiving care from a doctor who participates in a ... is nine percent lower -- than those members at traditional doctor practices, according to ... , “The promise of patient-centered, or value-based, care to deliver better quality care ...
    Breaking Medicine News(10 mins):Health News:Article on Incentivizing Weight Loss Mirrors Similar Motivations Surrounding Weight Loss Surgery, Says Dr. Feiz & Associates 2Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 2Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 3Health News:North Texas Acquisition Press Release 2Health News:DARA Responds To International Trends in Binge Drinking 2Health News:DARA Responds To International Trends in Binge Drinking 3Health News:Horizon BCBSNJ: 2014 Results Show Patient-Centered Care Continues to Deliver on Promise of Better Quality Care at a Lower Cost 2Health News:Horizon BCBSNJ: 2014 Results Show Patient-Centered Care Continues to Deliver on Promise of Better Quality Care at a Lower Cost 3
    ... everyday life, emotional support, and cultural and recreational activities ... were the results of a dissertation from the Sahlgrenska ... amongst teenagers have increased markedly in recent years, especially ... as many as seven out of ten teenage girls ...
    ... pointers for better food choices for kids , , ... children dive into the pool, head to the park, and ... they may also leave nutrition behind; nutrition essential to fuel ... nutrition expert Chere Bork, a registered dietitian with more than ...
    ... the 400,000-strong seniors group RetireSafe saluted the Pharmaceutical ... commitment to support legislation to cut prescription drug ... into the Medicare Part D Prescription Drug Program ... "a huge gift to older Americans caught in ...
    ... suggests a direct link between smoking and brain damage will ... of Neurochemistry . Researchers, led by Debapriya Ghosh and Dr ... have found that a compound in tobacco provokes white blood ... leading to severe neurological damage. The research centers ...
    ... 23 Anglo Coal South Africa,a wholly owned subsidiary ... Coalition (GBC) on HIV/AIDS, Tuberculosis and Malaria for its,pioneering ... South,Africa. Anglo American is South Africa,s leading private sector ... The Business Excellence Award for ...
    ... 23 Helix BioPharma Corp. (TSX, FSE: HBP; OTCQX: HXBPF) ... on the OTCQX International Market under the ticker symbol HXBPF. ... about the OTCQX International Market at www.otcqx.com ... enhanced local access to the largest capital market in the ...
    Cached Medicine News:Health News:How adolescent girls manage stress 2Health News:Summer is Here! Top Five Tips for Making Your Child's Summer Eating Habits Healthier 2Health News:New research discovers link between smoking and brain damage 2Health News:Anglo American's Coal Division in South Africa Wins Global Business Coalition Award for top International Workplace HIV and AIDS Programme 2Health News:Anglo American's Coal Division in South Africa Wins Global Business Coalition Award for top International Workplace HIV and AIDS Programme 3Health News:Helix Biopharma Corp. Begins Trading on the OTCQX International Market Listing as HXBPF 2Health News:Helix Biopharma Corp. Begins Trading on the OTCQX International Market Listing as HXBPF 3Health News:Helix Biopharma Corp. Begins Trading on the OTCQX International Market Listing as HXBPF 4
    ... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
    ... TOX/See™ is a 1-step, hand-held, point-of-care device ... metabolites in human urine. The TOX/See device ... commonly abused drugs in 3 to 8 minutes ... Each TOX/See cassette is individually packaged to maximize ...
    ... a 1-step, hand-held, point-of-care device for the qualitative ... urine. The TOX/See device can detect up ... in 3 to 8 minutes and requires only ... is individually packaged to maximize convenience and ease ...
    ... TOX/See™ is a 1-step, hand-held, point-of-care device for ... in human urine. The TOX/See device can ... abused drugs in 3 to 8 minutes and ... TOX/See cassette is individually packaged to maximize convenience ...
    Medicine Products: